Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great ...

By 2030, we won't be asking AI what the data says. I believe we'll be asking it what we should create next. The creative ...

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...

In general, cancer incidence is projected to rise significantly, with global cases expected to increase by 20% by 2030 and ...

The rate of surgical overtreatment of low-risk prostate cancer showed a significant decline between 2010 and 2024, reflecting ...

In this video, I will talk about Tempus AI (NASDAQ: TEM) and whether it is worth buying after the recent pullback. Watch the ...

As rising costs, workforce shortages, and aging populations strain traditional care models, AI is stepping in-not to replace doctors, but to super ...

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the“Company”) recently announced U.S. FDA approval of its innovative yield enhancement production process. This innovative process has demonstrated an ...

Meanwhile, Cadence and Intel Foundry are engaging in early design technology co-optimization for Intel 14A-E to establish the readiness of Cadence EDA flows for the next-generation advanced node.